Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (331-340 of 441) with videos related to

Pageof 45
Sort By:
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2024
Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre StudyCarine Nicolas, Quentin Domas, Stanislas Pol, et al.
Journal of Hepatology|October 4, 2021
Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitusVincent Mallet, Lucia Parlati, Alessandro Martinino, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
The New England Journal of Medicine|May 1, 2009
Telaprevir and peginterferon with or without ribavirin for chronic HCV infectionChristophe Hézode, Nicole Forestier, Geoffrey Dusheiko, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Gastroenterology|March 10, 2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia VasculitisCloé Comarmond, Marlène Garrido, Stanislas Pol, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Kidney International|November 21, 2022
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney DiseasePaul Martin, Ahmed A Awan, Marina C Berenguer, et al.
Pageof 45

Showing results (331-340 of 441) with videos related to

Sort By:
Pageof 45
Journal of Hepatology|December 15, 2010
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infectionMichael P Manns, Marc Bourlière, Yves Benhamou, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2024
Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre StudyCarine Nicolas, Quentin Domas, Stanislas Pol, et al.
Journal of Hepatology|October 4, 2021
Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitusVincent Mallet, Lucia Parlati, Alessandro Martinino, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
The New England Journal of Medicine|May 1, 2009
Telaprevir and peginterferon with or without ribavirin for chronic HCV infectionChristophe Hézode, Nicole Forestier, Geoffrey Dusheiko, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialMark S Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, et al.
Gastroenterology|March 10, 2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia VasculitisCloé Comarmond, Marlène Garrido, Stanislas Pol, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Kidney International|November 21, 2022
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney DiseasePaul Martin, Ahmed A Awan, Marina C Berenguer, et al.
Pageof 45